Mehdi Khalighi
YOU?
Author Swipe
View article: Enhancing the Diagnostic Accuracy of Amyloid PET: The Impact of MR-Guided PET Reconstruction
Enhancing the Diagnostic Accuracy of Amyloid PET: The Impact of MR-Guided PET Reconstruction Open
18 F-Florbetaben (FBB) uptake in the supratentorial cortex is indicative of amyloid positivity. Due to PET’s low spatial resolution, image noise, and spill-over of signal from adjacent white-matter into gray-matter, trained readers may pro…
View article: Optimization of Bloch-Siegert B1 Mapping Sequence for Maximum Signal to Noise
Optimization of Bloch-Siegert B1 Mapping Sequence for Maximum Signal to Noise Open
Adiabatic Bloch-Siegert B1+ mapping method addresses the long TE and high RF power deposition problems of conventional Bloch-Siegert B1+ mapping by introducing short frequency-swept ABS pulses with maximum sensitivity. Here, it is shown ho…
View article: [18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum
[18F]PI-2620 Tau PET signal across the aging and Alzheimer’s disease clinical spectrum Open
[18F]PI-2620 is a second generation tracer that has shown high binding affinity for tau aggregation in Alzheimer’s disease (AD). However, [18F]PI-2620 signal in a large sample spanning the healthy aging and AD clinical spectrum as well as …
View article: Early-Frame [<sup>18</sup>F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [<sup>15</sup>O]Water Gold Standard
Early-Frame [<sup>18</sup>F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [<sup>15</sup>O]Water Gold Standard Open
Cerebral blood flow (CBF) may be estimated from early-frame PET imaging of lipophilic tracers, such as amyloid agents, enabling measurement of this important biomarker in participants with dementia and memory decline. Although previous met…
View article: Validation of early‐frame 18F‐FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients
Validation of early‐frame 18F‐FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients Open
Background This study aimed to validate early [ 18 F]‐FDG (eFDG) imaging for the quantification of cerebral blood flow (CBF), enabling dual‐marker imaging of perfusion and metabolism with a single tracer. Method 19 participants with memory…
View article: Segmenting Cervical Arteries in Phase Contrast Magnetic Resonance Imaging Using Convolutional Encoder–Decoder Networks
Segmenting Cervical Arteries in Phase Contrast Magnetic Resonance Imaging Using Convolutional Encoder–Decoder Networks Open
Phase contrast (PC) magnetic resonance imaging (MRI) is a primary method used to quantify blood flow. Cerebral blood flow (CBF) is an important hemodynamic parameter to characterize cerebrovascular and neurological diseases. However, a cri…
View article: Generative Adversarial Network–Enhanced Ultra-Low-Dose [<sup>18</sup>F]-PI-2620 τ PET/MRI in Aging and Neurodegenerative Populations
Generative Adversarial Network–Enhanced Ultra-Low-Dose [<sup>18</sup>F]-PI-2620 τ PET/MRI in Aging and Neurodegenerative Populations Open
The clinical readings of deep learning-enhanced ultra-low-dose τ PET images were consistent with those performed with full-dose imaging, suggesting the possibility of reducing the dose and enabling more frequent examinations for dementia m…
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Supplementary Table S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Vital signs of the patients administered with [18F]DASA-23
View article: Supplementary Figure S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Post-therapy Imaging of IC-1
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in healthy volunteers
View article: Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 Radiosynthesis
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Clinical Characteristics of patients imaged with [18F]DASA-23
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Purpose:Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the developmen…
View article: Supplementary Figure S7 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S7 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
PKM2 analysis in TP459 neurospheres
View article: Supplementary Figure S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Western blot analysis of PKM2 expression in IC-1
View article: Supplementary Figure S9 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S9 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-3
View article: Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Hematology laboratory testing results of patients imaged with [18F]DASA-23
View article: Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S5 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Hematology laboratory testing results of patients imaged with [18F]DASA-23
View article: Supplementary Table S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S6 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Blood chemistry laboratory testing results of the patients imaged with [18F]DASA-23
View article: Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in brain tumor patients
View article: Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in brain tumor patients
View article: Supplementary Figure S10 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S10 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-4
View article: Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in healthy volunteers
View article: Supplementary Figure S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S4 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 time activity curves